Texas AG Sues Big Pharma drug manufacturers and Pharmacy Benefit Managers for an illegal pricing scheme that raised insulin prices by 1,000%.

In 2022, Paxton announced an investigation into the pricing of insulin due to its dramatically increased costs over time, targeting not just insulin manufacturers but also entities within the supply chain. The investigation aimed at understanding if there were any violations of law in how insulin prices were inflated. Insulin prices have dramatically increased over the years, which has become a significant issue for many, especially those with diabetes who require insulin for survival. This rise in pricing has led to widespread concern about affordability and accessibility of the drug. Paxton's investigation was spurred by these concerns over the affordability of insulin. The investigation aimed to understand why insulin prices were so high and whether there were any violations of law in pricing practices by pharmaceutical companies or other entities in the insulin supply chain.

The investigation potentially included insulin manufacturers, pharmacy benefit managers (PBMs), health insurers, and other parties involved in the distribution and pricing of insulin. Paxton looked into whether there were antitrust issues, price fixing, or other practices that contributed to the high cost of insulin, potentially violating consumer protection laws.

Paxton has sued pharmaceutical companies for other reasons, like his lawsuit against Pfizer regarding misrepresentation of COVID-19 vaccine efficacy and censorship. These actions show Paxton's willingness to challenge large pharmaceutical companies on legal grounds.